Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid-19: European Journal of Neurology

M. Cappellari, A. Zini, D. Sangalli, A. Cavallini, M. Reggiani, F.N. Sepe, N. Rifino, G. Giussani, D. Guidetti, M. Zedde, S. Marcheselli, M. Longoni, S. Beretta, V. Sidoti, D.M. Papurello, A. Giossi, P. Nencini, M. Plocco, M. Balestrino, E. RotaD. Toni

Research output: Contribution to journalArticlepeer-review

Abstract

Background and purpose: Comorbidity of acute ischaemic stroke with Covid-19 is a challenging condition, potentially influencing the decision of whether to administer intravenous thrombolysis (IVT). We aimed to assess the 1-month outcome in ischaemic stroke patients with Covid-19 infection who received IVT alone or before thrombectomy (bridging therapy). Methods: As a collaboration initiative promoted by the Italian Stroke Organization, all Italian stroke units (n = 190) were contacted and invited to participate in data collection on stroke patients with Covid-19 who received IVT. Results: Seventy-five invited centers agreed to participate. Thirty patients received IVT alone and 17 received bridging therapy between 21 February 2020 and 30 April 2020 in 20 centers (n = 18, Northern Italy; n = 2, Central Italy). At 1 month, 14 (30.4%) patients died and 20 (62.5%) survivors had a modified Rankin Scale (mRS) score of 3 to 5. At 24 to 36 hours, asymptomatic intracerebral hemorrhage (ICH) was reported in eight (17.4%) patients and symptomatic ICH (sICH) in two (4.3%) patients. Causes of death were severe ischaemic stroke (n = 8), a new ischaemic stroke (n = 2), acute respiratory failure (n = 1), acute renal failure (n = 1), acute myocardial infarction (n = 1), and endocarditis (n = 1). In survivors with a 1-month mRS score of 3 to 5, baseline glucose level was higher, whereas endovascular procedure time in cases of bridging therapy was longer. Baseline National Institutes of Health Stroke Scale glucose and creatinine levels were higher in patients who died. Conclusions: Intravenous thrombolysis for patients with stroke and Covid-19 was not a rare event in the most affected areas by pandemic, and rates of 1-month unfavorable outcomes were high compared to previous data from the pre–Covid-19 literature. However, risk of sICH was not increased. © 2020 European Academy of Neurology
Original languageEnglish
Pages (from-to)2641-2645
Number of pages5
JournalEur. J. Neurol.
Volume27
Issue number12
DOIs
Publication statusPublished - 2020

Keywords

  • bridging therapy
  • Covid-19
  • outcome
  • stroke
  • thrombolysis
  • alteplase
  • creatinine
  • glucose
  • fibrinolytic agent
  • acute heart infarction
  • acute kidney failure
  • acute respiratory failure
  • aged
  • Article
  • brain hemorrhage
  • brain ischemia
  • cohort analysis
  • controlled study
  • coronavirus disease 2019
  • creatinine blood level
  • endocarditis
  • endovascular surgery
  • female
  • glucose blood level
  • human
  • major clinical study
  • male
  • middle cerebral artery
  • National Institutes of Health Stroke Scale
  • priority journal
  • Rankin scale
  • reverse transcription polymerase chain reaction
  • stroke patient
  • stroke unit
  • survivor
  • thrombectomy
  • treatment outcome
  • blood
  • cause of death
  • complication
  • epidemiology
  • fibrinolytic therapy
  • intravenous drug administration
  • Italy
  • mortality
  • pandemic
  • procedures
  • survival analysis
  • very elderly
  • Aged
  • Aged, 80 and over
  • Blood Glucose
  • Cause of Death
  • COVID-19
  • Creatinine
  • Female
  • Fibrinolytic Agents
  • Humans
  • Injections, Intravenous
  • Ischemic Stroke
  • Male
  • Pandemics
  • Survival Analysis
  • Thrombectomy
  • Thrombolytic Therapy
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid-19: European Journal of Neurology'. Together they form a unique fingerprint.

Cite this